• Kura Oncology announced an Oct. 13, 2026 investor webcast with Caspian Therapeutics to outline Caspian’s launch.
• Management will review preclinical KO-7246 data that were already presented in an oral session at the EASD annual meeting.
• KO-7246 is positioned as an oral menin inhibitor for metabolic disease, with development aimed at restoring beta-cell function and insulin production.
• Caspian plans a Phase 1 program for KO-7246, shifting menin-inhibitor work from oncology into diabetes-focused clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070715PRIMZONEFULLFEED9841054) on October 07, 2026, and is solely responsible for the information contained therein.